Loading…
Success Stories
From Fortune 500 partnerships to startup launches, ILG has a track record of turning intellectual property into revenue across every major industry vertical.
Marquee partnerships and landmark transactions
Roche®
Drug discovery collaboration to validate platform for start-up company. Research fees and shared IP rights with Roche®.
P&G®
License and joint development with P&G® for dermatology applications. Research fees and royalties. Applications limited. Shared IP.
$30M+ project with Exxon®
Discovery collaboration with Exxon® advanced materials. Combi-Chem platform to discover new class of advanced materials. Upfront, milestones, license royalties on the materials. Non-exclusive on use of platform in addition to residual royalties from future inventions.
Mitsui
Formed global partnership to develop, manufacture, distribute and license advanced materials. Shared research, IP and promotion. Mitsui to build manufacturing plant and obtain Japanese market revenue only.
$10M+ project with Ciba®
Licensed technology and formed 50/50 JV with Ciba® to launch new business in Europe as extension of US business. Upfront payment, fully budgeted operation to develop applications and customers. Royalties and IP rights in remainder of world.
$12M NIST grant with 3M®
Joint development with 3M® for development of flat panel display application using advanced materials. Research fees, royalties and IP rights. Secured NIST grant of $12M in partnership.
GM®
Multi-year contract with GM US to provide marketing, pricing, logistical analysis and projections. Designed customized disparate database, established secure ISP connections and supported both ongoing and consulting work for client.
Eli Lilly®
Collaborative research informatics deal. Designed product for Lilly® with residual ownership (commercial IP rights) for industry distribution after 12 months. Research fees and promotion support.
Amgen®
Collaborative research informatics deal. Designed product for Amgen® with residual ownership for industry distribution after 12 months. Research fees and promotion support. Both Lilly® and Amgen® products launched new business into pharmaceutical channel.
$12M NIST grant with IBM®
Joint research with IBM® and Georgia Tech. Obtained NIST grant ($12M) to develop advanced materials for electronic applications.
$25M revenue in 6 years
Started up advanced materials business. Grew 25 patents and 5 people to 80 people and $25 million in revenue within 6 years. Established global business using Nippon Zeon® and French TOTAL® joint venture partners.
IPO
CEO, Founder, launched company and took public.
30% return on 20+ investments
Invested in over 20 firms in both life science and hi-tech, achieving a 30% return overall.
NIH + multi-party approval
Negotiated license rights for Human Embryonic Stem Cell lines. Required approval of four parties including NIH and University of Wisconsin. Also extended research agreement for specific applications of stem cells.
$50M+ presented, $26M award
Led teams to apply and present for grant and joint funding from NIST and NIH. Presented five times (over $50M), getting awards four times including a $26M award, the second largest in the history of NIST. Also managed three of these.
Browse by industry vertical
Sourced product from China, designed retail packaging, and launched internet and retail sales and marketing campaign driving sales/profits. The My Lil' Mouse product line sold on thousands of websites and has been retired with the rise of tablets and other devices.
Sourced product from China, designed retail packaging, and launched internet and retail sales and marketing campaign driving sales/profits. Our gaming mice currently sell on thousands of websites.
Sourced product from China, designed retail packaging and launched internet and retail sales and marketing campaign driving sales/profits. This product currently sells online and in brick and mortar retailers throughout the Midwest and east coast.
Launched internet and retail sales campaign, and rebuilt product and packaging, to drive sales and meet consumer demand.
Roche®
Drug discovery collaboration to validate platform for start-up company. Research fees and shared IP rights with Roche®.
Non-exclusive license for vaccine technology. Upfront fees, milestones, royalties, and IP rights.
P&G®
License and joint development with P&G® for dermatology applications. Research fees and royalties. Applications limited. Shared IP.
Research collaboration to validate platform for start-up company. Research fees and shared IP rights.
Planning and leading of translational biology, pharmacology, and toxicology functions in support and advancement of medical work.
Created and led new RA research program, set disease control strategies in metabolic and muscular skeletal disease at large pharmaceutical company.
Sourced product from China, designed retail packaging and launched internet and retail sales marketing campaign driving sales/profits.
$30M+ project with Exxon®
Discovery collaboration with Exxon® advanced materials. Combi-Chem platform to discover new class of advanced materials. Upfront, milestones, license royalties on the materials. Non-exclusive on use of platform in addition to residual royalties from future inventions.
Mitsui
Formed global partnership to develop, manufacture, distribute and license advanced materials. Shared research, IP and promotion. Mitsui to build manufacturing plant and obtain Japanese market revenue only.
$8M+ project with Ciba®
Joint development and license program using advanced materials to replace epoxy PCBs. Research fees, shared IP. Ciba to manufacture and distribute. Royalties.
$10M+ project with Ciba®
Licensed technology and formed 50/50 JV with Ciba® to launch new business in Europe as extension of US business. Upfront payment, fully budgeted operation to develop applications and customers. Royalties and IP rights in remainder of world.
Nippon Zeon®
Licensed technology and formed JV to share research, IP and promotion rights. Nippon Zeon® to have Japanese market. NZ conducts research solely until tech validated. NZ to provide monomer for US and Europe. NZ pays minimum and variable royalty. Shared promotion.
$12M NIST grant with 3M®
Joint development with 3M® for development of flat panel display application using advanced materials. Research fees, royalties and IP rights. Secured NIST grant of $12M in partnership.
BASF®
Three-way joint development to develop high performance polymer materials product. BASF® to manufacture and shared distribution rights. Research fees and royalties.
$8M NIST grant
Secured NIST grant of $8M in partnership. Joint development program. Research fees and royalties. Shared IP.
McDermott®
Partnership to design and produce fuel cells. NIST application for $8M. Research fees, IP rights, and shared income. McDermott® to build manufacturing facility. Joint research.
Business development on first gas turbine commercialized with catalytic combustor.
Due diligence, negotiation and acquisition of company holding unique regeneration technology.
Exclusive field of use. Upfront payment, running royalties, minimums, sub-licensing, IP costs, diligence.
Non-exclusive. Upfront payment, running royalties, minimums, diligence, supply contract.
Exclusive field of use. Upfront payment, running royalties, minimums, IP costs, diligence, sublicensing, 1yr tech transfer contract.
Exclusive field of use, equity, running royalties, minimums, diligence, sublicensing, 1yr R&D contract.
GM®
Multi-year contract with GM US to provide marketing, pricing, logistical analysis and projections. Designed customized disparate database, established secure ISP connections and supported both ongoing and consulting work for client.
Eli Lilly®
Collaborative research informatics deal. Designed product for Lilly® with residual ownership (commercial IP rights) for industry distribution after 12 months. Research fees and promotion support.
Amgen®
Collaborative research informatics deal. Designed product for Amgen® with residual ownership for industry distribution after 12 months. Research fees and promotion support. Both Lilly® and Amgen® products launched new business into pharmaceutical channel.
Designed strategy and co-founded company within corporate parent. Raised money, built staff, located merger partner, negotiated spin-out and merged with partner. Reorganized staff, modified strategy, restructured balance sheet and launched new business with revenue in first year.
Exclusive field of use, equity, upfront payment, running royalties, minimums, diligence, sublicensing, 2yr R&D contract.
$12M NIST grant with IBM®
Joint research with IBM® and Georgia Tech. Obtained NIST grant ($12M) to develop advanced materials for electronic applications.
Out-licensed technology from University of California; co-founded company with four partners. Applied for SBIR funding and launched clinical trials.
Launch in 7 months
Initiated and designed strategy for new company. Formed 50/50 joint venture with biotech firm. Incorporated new stand-alone company. Launched new company into combinatorial chemistry business within 7 months.
$5M raised
Completed business plan, investor presentation, organized road show and helped raise $5 million for high-tech company.
Revamped corporate strategy, business plan and investor presentation for Nuada Pharmaceuticals. Secured additional funding from existing investor group.
Spun out business unit, acquired competing firm, and secured equity and debt financing from parent company.
$25M revenue in 6 years
Started up advanced materials business. Grew 25 patents and 5 people to 80 people and $25 million in revenue within 6 years. Established global business using Nippon Zeon® and French TOTAL® joint venture partners.
IPO
CEO, Founder, launched company and took public.
30% return on 20+ investments
Invested in over 20 firms in both life science and hi-tech, achieving a 30% return overall.
NIH + multi-party approval
Negotiated license rights for Human Embryonic Stem Cell lines. Required approval of four parties including NIH and University of Wisconsin. Also extended research agreement for specific applications of stem cells.
Negotiated new agreement for stem cell rights. Had to rebuild poor relationships and trust issues.
30+ agreements
Negotiated over 30 agreements to conduct research in exchange for payments and IP rights with universities in the US and Europe.
$50M+ presented, $26M award
Led teams to apply and present for grant and joint funding from NIST and NIH. Presented five times (over $50M), getting awards four times including a $26M award, the second largest in the history of NIST. Also managed three of these.
$2M–$20M per agreement
Negotiated and managed over 25 major raw material and other key purchasing agreements ranging in value from $2M to over $20M.
Negotiated and managed a large number of single and multi-year agreements for manufacturing, supply, distribution, consulting, market research, press and public relations, and legal and financial services.
Negotiated two labor agreements for four of company's manufacturing operations.
Partners & Collaborators Include
Whether you have a patent, a product, or a company to grow — we have the track record to deliver.
Schedule a Consultation